Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow SNY
Sanofi (SNY) EV/Sales
As of 9 October 2026, Sanofi (SNY) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 1.8× (September 2022) to 3.5× (August 2015); the current reading is higher than 3% of that period. That is below the Drug Manufacturers General industry median of 3.9× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | (8.86%) |
| FY2024 | 2.7× | 2.14% |
| FY2023 | 2.7× | (1.80%) |
| FY2022 | 2.7× | 30.01% |
| FY2021 | 2.1× | (0.78%) |
| FY2020 | 2.1× | (10.02%) |
| FY2019 | 2.3× | (4.65%) |
| FY2018 | 2.4× | (12.96%) |
| FY2017 | 2.8× | (6.04%) |
| FY2016 | 3.0× | 5.05% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.1× | (11.78%) |
| Mar 2026 | 2.4× | (3.46%) |
| Dec 2025 | 2.5× | (9.54%) |
| Sep 2025 | 2.7× | 3.95% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.6× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.3× |
| NVO Novo Nordisk A/S compare | 3.6× |
| AZN AstraZeneca PLC compare | 4.4× |
| NVS Novartis AG compare | 5.5× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| Drug Manufacturers General industry median | 3.9× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)